Villasis, Alexandra D.

HRN: 22-70-95  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/14/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
03/14/2023
03/20/2023
IV
150mg
Q6h
PCAP C
Waiting Final Action 
03/16/2023
CEFTRIAXONE 1G (VIAL)
03/16/2023
03/22/2023
IV
600 Mg
OD
Pneumonia
Waiting Final Action 
03/16/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
03/16/2023
03/22/2023
IV
90 Mg
Q24
Pneumonia
Waiting Final Action 
03/19/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/19/2023
03/26/2023
IV DRIP
600mg
Q 6 Hours
PCAP- C
Waiting Final Action 
03/20/2023
MUPIROCIN 2%, 15G (TUBE)
03/20/2023
03/27/2023
TOPICAL
N/A
BID
Skin Infection
Waiting Final Action 
03/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
03/21/2023
03/21/2023
IVTT
30mg
Q8
Pcap C
Waiting Final Action 
03/21/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
03/21/2023
03/28/2023
IVT
60mg
Q8
PCAP
Waiting Final Action 
03/23/2023
FLUCONAZOLE 2MG/ML, 100ML (VIAL)
03/23/2023
03/30/2023
IV
70mg Ld, Then 35mg Od
Od
Pcap D
Waiting Final Action 
04/03/2023
CIPROFLOXACIN 500MG (TAB)
04/03/2023
04/09/2023
PO
60mg
Bid
Pneumonia
Waiting Final Action 
04/09/2023
AZITHROMYCIN 200MG/5ML, 15ML SUSPENSION (SUSP)
04/09/2023
04/13/2023
ORAL
1.5ml
OD
Pneumonia
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: